Volume 72, Issue 3 (June 2014)
Tehran Univ Med J 2014, 72(3): 174-180 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Moaieri H, Modarresi Mosalla Z, Shariat M, Haghshenas Z, Naderi F. Influence of GnRH analogue on body mass index in girls with precocious puberty: a prospective study. Tehran Univ Med J 2014; 72 (3) :174-180
URL: http://tumj.tums.ac.ir/article-1-6036-en.html
URL: http://tumj.tums.ac.ir/article-1-6036-en.html
Heshmat Moaieri1 
, Zeinab Modarresi Mosalla * 2, Mamak Shariat3 , Zahra Haghshenas1 , Fariba Naderi1
, Zeinab Modarresi Mosalla * 2, Mamak Shariat3 , Zahra Haghshenas1 , Fariba Naderi1
1- Department of Pediatric Medi-cine, Valiasr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
2- Department of Pediatric Medi-cine, Valiasr Hospital, Tehran University of Medical Sciences, Tehran, Iran. ,z.modarresy@gmail.com
3- Maternal, Fetal and Neonatal Research Center, Tehran University of Medical Sciences, Tehran, Iran.
2- Department of Pediatric Medi-cine, Valiasr Hospital, Tehran University of Medical Sciences, Tehran, Iran. ,
3- Maternal, Fetal and Neonatal Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Abstract: (5796 Views)
Background: Gonadotropin-releasing hormone analog (GnRHa) therapy is used in central precocious puberty (CPP) worldwide and it is the treatment of choice for this condition. Many of the previous studies concerning the effect of gonadotropin-releasing hormone analog (GnRHa) therapy on height. Much less attention has been paid to changes in body weight. However, concerns have been expressed that CPP may be associated with increased body mass index (BMI) both at initial presentation and during GnRH agonist treatment, but it is controversial in some studies.
Methods: We have retrospectively reviewed 52 female patients that the majority of them had CPP. We assessed height, height SDS, weight, weight SDS, BMI and BMI SDS. All patients were treated with GnRHa over 12 months. The variables were evalu-ated at 0, 6 and 12 months after initiation of treatment.8 girls received growth hormone concomitantly. Also bone age and sexual maturity were measured. Bone age was assessed according to the Greulich-Pyle method and sexual maturation was classified according to the Marshall-Tanner method.
Results: Before the initiation of therapy, the girls had a mean BMI SD score for chronological age of 0.80± 1.18 after 6 months of therapy BMI SDS was 0.82± 1.15 and after 12 months was 0.82± 1.28 the P value is 0.909 and it is not statistically signif-icant. Height SD score for chronological age was 0.41± 1.65 before the initiation of therapy and was 0.41± 1.65 after 6 months and 0.43± 1.60 after 12 months of therapy. The P= 0.66 and it is not statistically significant. Eight girls received growth hormone concomitantly, in this group increasing height SDS is statistically significant P= 0.044 but increasing BMI SDS is not significant.
Conclusion: Gonadotropin-releasing hormone analog (GnRHa) therapy in central precocious puberty (CPP) is safe for BMI and increasing of BMI is not significant, long- term follow-up study is required to elucidate whether GnRHa treatment affects adult obesity. Using growth hormone concomitantly, the effect on increasing height is significant.
Type of Study: Original Article |
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
